-
Product Insights
Net Present Value Model: ALLO-316
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ALLO-316 Drug Details ALLO-316 is under...
-
Product Insights
Net Present Value Model: ALLO-501
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ALLO-501 Drug Details ALLO-501 is under...
-
Product Insights
Net Present Value Model: ALLO-715
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ALLO-715 Drug Details ALLO-715 is under...
-
Product Insights
Net Present Value Model: UCART-19
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model UCART-19 Drug Details UCART19 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALLO-316
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALLO-316 Drug Details ALLO-316 is under development for the treatment of acute myeloid leukemia,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – IOV-4001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IOV-4001 Drug Details IOV-4001 is under development for treatment of unresectable or metastatic melanoma...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALLO-501
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALLO-501 Drug Details ALLO-501 is under development for the treatment of relapsed and refractory...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALLO-605
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALLO-605 Drug Details ALLO-605 is under development for the treatment of relapsed/refractory multiple myeloma....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALLO-715
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALLO-715 Drug Details ALLO-715 is under development for the treatment of relapsed and refractory...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – UCART-19
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry UCART-19 Drug Details UCART19 is under development for the treatment of B-cell acute lymphoblastic...